Amphastar Pharmaceuticals, Inc. (AMPH) Stock: Price, Forecast & Analyst Target
Amphastar Pharmaceuticals, Inc. (AMPH) — MoonshotScore 86/100 (Exceptional band), calculated Nov 18, 2026. Price $28.11 (-5.39%), as of the Nov 19, 2026 trading session; market cap $1.20B.
Educational signal · not a buy or sell recommendation · How to read this
Amphastar Pharmaceuticals, Inc. · AMPH · NASDAQ
Amphastar Pharmaceuticals, Inc. develops, manufactures, and markets generic and proprietary injectable, inhalation, and intranasal products. The company operates in the United States, China, and France, serving hospitals, care facilities, and clinics.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Amphastar Pharmaceuticals (AMPH)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and durable growth, at a cheap price, though the balance sheet is only middling; the market is already moving on it. Business Quality: Elite; Financial Safety: Okay; Valuation: Cheap; Growth Durability: Compounding; Momentum: Surging.
- quarterly revenue $208M (Q3 FY2026, quarter ended Sep 2026)
- EPS beat 5 of the last 8 reports
- Altman Z 2.47 · Piotroski F 6
Helping: business quality, an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 83 | Exceptional | |
| 83 | Exceptional | |
| 83 | Exceptional | |
| 86 | Exceptional | |
| 86 | Exceptional | |
| 86 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $28.11 | |
| Change on the day | -5.39% | |
| 52-week range | $16.65 – $31.00 | |
| Market capitalisation | $1.20B | — |
| Price / earnings (trailing) | 12.93 | |
| Shares traded on the day | 662.5K |
Price & events
Other perspectives
Council score for Amphastar Pharmaceuticals (AMPH): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
6 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 17, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Amphastar Pharmaceuticals (AMPH), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Amphastar Pharmaceuticals, Inc. (AMPH) is listed on NASDAQ. It employs 1,976 people and is led by Yongfeng Zhang. In Q3 FY2026 it reported revenue of $208M and net income of $38M. The market values it at $1.20B.
What do the latest results show for Amphastar Pharmaceuticals (AMPH)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $208M. Against analyst estimates the company has EPS beat 5 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $208M | $38M | $0.87 (diluted) |
| Q2 FY2026 | $184M | $30M | $0.69 (diluted) |
| Q1 FY2026 | $171M | $6M | $0.14 (diluted) |
| Q4 FY2025 | $183M | $24M | $0.52 (diluted) |
What are the financial strengths and risks for Amphastar Pharmaceuticals (AMPH)?
Short answer
The MoonshotScore pillars rate business quality, an attractive price, durable growth, positive momentum as strengths. The distress and quality screens read Altman Z 2.47 · Piotroski F 6. Trailing ratios: ROE 12.4% · ROA 5.2% · current ratio 3.32.
What should you watch next at Amphastar Pharmaceuticals (AMPH)?
Short answer · as of
Current published price targets run low $23.00 · high $23.00 · consensus $23.00 · median $23.00 against a quoted price of $28.11 (as of Nov 19, 2026).
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Amphastar Pharmaceuticals compare with its peers?
Short answer
Amphastar Pharmaceuticals's score ranks 4th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $3.08 Nov 19, 2026 | $1.13B | 95 5-pillar Nov 18, 2026 | |
| $69.13 Nov 19, 2026 | $1.57B | 94 5-pillar Nov 18, 2026 | |
| $36.48 Nov 19, 2026 | $1.46B | 92 5-pillar Nov 18, 2026 | |
| Amphastar Pharmaceuticals (AMPH) — this page | $28.11 | $1.20B | 86 |
| $34.08 Nov 19, 2026 | $1.38B | 78 5-pillar Nov 18, 2026 | |
| $14.85 Nov 19, 2026 | $12.4B | 77 5-pillar Nov 18, 2026 | |
| $13.45 Nov 19, 2026 | $2.34B | 70 5-pillar Nov 18, 2026 | |
| $25.21 Nov 19, 2026 | $783M | 58 5-pillar Nov 18, 2026 | |
| $38.54 Nov 19, 2026 | $45.0B | 57 5-pillar Nov 18, 2026 | |
| $4.36 Nov 19, 2026 | $2.16B | 47 5-pillar Nov 18, 2026 | |
| $4.71 Nov 19, 2026 | $780M | 39 5-pillar Nov 18, 2026 | |
| $19.88 Nov 19, 2026 | $22.8B | 35 5-pillar Nov 18, 2026 | |
| $7.81 Nov 19, 2026 | $491M | 34 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $23.00 – $23.00
- Consensus target
- $23.00
- Median target
- $23.00
Consensus record · Captured .
Measured against a quoted price of $28.11 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 500 records, those within the last 180 days, newest dated Nov 5, 2026
- Transactions
- 30
- Identified insiders
- 9
- Purchases
- 0
- Sales
- 7
- Other transactions
- 23
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held AMPH in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported AMPH in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Amphastar Pharmaceuticals (AMPH)?
Investor Questions: AMPH Stock
These answers are editorial: 1 of these 9 answers is drawn from the AMPH research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for AMPH?
AMPH carries the MoonshotScore stated above — the Exceptional band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Amphastar Pharmaceuticals, Inc. develops, manufactures, and markets generic and proprietary injectable, inhalation, and intranasal products.
Is AMPH a good stock to buy?
Stock Expert AI does not rate AMPH buy, sell or hold. Amphastar Pharmaceuticals, Inc. carries a MoonshotScore, in the Exceptional band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the AMPH stock price today?
The last price recorded for Amphastar Pharmaceuticals, Inc. (AMPH), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the AMPH price target?
The analyst consensus price target for Amphastar Pharmaceuticals, Inc. (AMPH), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
What are the key growth opportunities for AMPH in healthcare?
Amphastar Pharmaceuticals, Inc. has several key growth opportunities within the healthcare sector. These include expanding its generic injectable product portfolio to capitalize on the increasing demand for affordable medications.
What are the key factors to evaluate for AMPH?
Amphastar Pharmaceuticals, Inc. (AMPH) holds a MoonshotScore in the high range. To weigh it, compare the trailing P/E under Price & valuation with the analyst view under Analyst targets & estimates on this page. Not financial advice.
How frequently does AMPH data refresh on this page?
AMPH's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven AMPH's recent stock price performance?
Amphastar Pharmaceuticals, Inc. (AMPH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diverse product portfolio of generic and proprietary injectables and inhalation products. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider AMPH overvalued or undervalued right now?
The trailing P/E of Amphastar Pharmaceuticals, Inc. (AMPH) is listed under Price & valuation, and the analyst consensus target under Analyst targets & estimates, on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 21 figures on this page — 13 from Financial Modeling Prep (FMP), 7 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com